Department of Nursing Science, Gachon University College of Nursing, Incheon, Korea.
Department of Nursing, Chosun University College of Medicine, Gwangju, Korea.
Investig Clin Urol. 2017 May;58(3):152-163. doi: 10.4111/icu.2017.58.3.152. Epub 2017 Apr 28.
To assess the effectiveness and safety of robot-assisted radical prostatectomy (RARP) versus laparoscopic radical prostatectomy (LRP) in the treatment of prostate cancer.
Existing systematic reviews were updated to investigate the effectiveness and safety of RARP. Electronic databases, including Ovid MEDLINE, Ovid Embase, the Cochrane Library, KoreaMed, Kmbase, and others, were searched through July 2014. The quality of the selected systematic reviews was assessed by using the revised assessment of multiple systematic reviews (R-Amstar) and the Cochrane Risk of Bias tool. Meta-analysis was performed by using Revman 5.2 (Cochrane Community) and Comprehensive Meta-Analysis 2.0 (CMA; Biostat). Cochrane Q and I2 statistics were used to assess heterogeneity.
Two systematic reviews and 16 additional studies were selected from a search performed of existing systematic reviews. These included 2 randomized controlled clinical trials and 28 nonrandomized comparative studies. The risk of complications, such as injury to organs by the Clavien-Dindo classification, was lower with RARP than with LRP (relative risk [RR], 0.44; 95% confidence interval [CI], 1.23-0.85; p=0.01). The risk of urinary incontinence was lower (RR, 0.43; 95% CI, 0.31-0.60; p<0.000001) and the potency rate was significantly higher with RARP than with LRP (RR, 1.38; 95% CI, 1.11-1.70; I=78%; p=0.003). Regarding positive surgical margins, no significant difference in risk between the 2 groups was observed; however, the biochemical recurrence rate was lower after RARP than after LRP (RR, 0.59; 95% CI, 0.48-0.73; I=21%; p<0.00001).
RARP appears to be a safe and effective technique compared with LRP with a lower complication rate, better potency, a higher continence rate, and a decreased rate of biochemical recurrence.
评估机器人辅助根治性前列腺切除术(RARP)与腹腔镜根治性前列腺切除术(LRP)治疗前列腺癌的疗效和安全性。
对现有的系统评价进行更新,以调查 RARP 的疗效和安全性。通过电子数据库,包括 Ovid MEDLINE、Ovid Embase、Cochrane 图书馆、KoreaMed、Kmbase 等,检索至 2014 年 7 月。使用修订后的多项系统评价评估工具(R-Amstar)和 Cochrane 偏倚风险工具评估所选系统评价的质量。使用 Revman 5.2(Cochrane 协作网)和 Comprehensive Meta-Analysis 2.0(CMA;Biostat)进行荟萃分析。使用 Cochrane Q 和 I² 统计量评估异质性。
从对现有系统评价的检索中,共选择了 2 项系统评价和 16 项额外的研究。这些研究包括 2 项随机对照临床试验和 28 项非随机对照研究。根据 Clavien-Dindo 分类,RARP 组的并发症风险(如器官损伤)低于 LRP 组(RR,0.44;95%置信区间 [CI],1.23-0.85;p=0.01)。RARP 组的尿失禁风险较低(RR,0.43;95%CI,0.31-0.60;p<0.000001),勃起功能恢复率显著高于 LRP 组(RR,1.38;95%CI,1.11-1.70;I=78%;p=0.003)。关于阳性切缘,两组之间的风险无显著差异;然而,RARP 后生化复发率低于 LRP 后(RR,0.59;95%CI,0.48-0.73;I=21%;p<0.00001)。
与 LRP 相比,RARP 似乎是一种安全有效的技术,其并发症发生率较低,勃起功能恢复率较高,尿失禁发生率较低,生化复发率较低。